title: Older statin initiators in Finland - cardiovascular risk profiles and persistence of use.
abstract: OBJECTIVE
  The benefits of statin treatment initiated in advanced age are largely unknown; however, good adherence to treatment is essential for beneficial effects to be achieved also when treating older people. This study characterizes older statin initiators, including their cardiovascular risk profiles and morbidity, and investigates patterns of treatment persistence.
  
  
  METHODS
  Longitudinal register-based study. All statin initiators in Finland aged ≥70 in 2000-2008 (n = 157,709) were identified from the nationwide Prescription Register. Using information from comprehensive health registers, the initiators were classified as having low, moderate, or high cardiovascular risk. For the initiators in 2000 and 2004, patterns of persistence were evaluated over a 4-year follow-up using the anniversary method.
  
  
  RESULTS
  The annual number of statin initiators increased from 15,082 to 19,728; the proportion of those aged ≥80 increased from 12.9 to 25.8 %. The prevalence of coronary heart disease at statin initiation decreased from 45.5 to 28.1 %. Only every tenth initiator (9.2-11.7 %) was estimated to have low cardiovascular risk each year. Four in five initiators (76.9-80.5 %) persisted with statin treatment after 1 year. The probability to survive and remain persistent for 4 years was 51.6 % and the probability to discontinue within the first year without restarting in the subsequent 3 years was 9.1 %. There were no noticeable differences in persistence across the risk groups.
  
  
  CONCLUSIONS
  Long-term persistence with statins among older people was good across cardiovascular risk groups. These findings are consistent with the notion that the decision on long-term continuation of statin use is made during the first year of treatment.
authors.affiliation: Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Medisiina C, 6. krs., Kiinanmyllynkatu 10, 20520, Turku, Finland, eveupm@utu.fi.
authors.forename: Eveliina
authors.initials: E
authors.lastname: Upmeier
authors.forename: Maarit Jaana
authors.initials: MJ
authors.lastname: Korhonen
authors.forename: Maria
authors.initials: M
authors.lastname: Rikala
authors.forename: Arja
authors.initials: A
authors.lastname: Helin-Salmivaara
authors.forename: Risto
authors.initials: R
authors.lastname: Huupponen
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D055118:Medication Adherence; D012042:Registries; D012307:Risk Factors; D013997:Time Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors